Han Eol Jeong

Han Eol Jeong

Auto-generated profile, based on publicly available information

Han Eol Jeong

School of Pharmacy Sungkyunkwan University Suwon South Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
YNYunha Noh
Yunha Noh
HJHan Eol Jeong
Han Eol Jeong
ACAhhyung Choi
Ahhyung Choi
ECEun-Young Choi
Eun-Young Choi
BPBjörn Pasternak
Björn Pasternak
JSJu-Young Shin
Ju-Young Shin
The prevalence of allergic diseases has risen worldwide, especially among children and adolescents.1,2 Great efforts have been dedicated to identifying factors associated with allergic disease,3 and data have suggested associations between allergic diseases and acid-suppressive medication (ASM) use in fetal and early life.4-8 Meanwhile, ASMs, including proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs), are frequently used during pregnancy to treat gastroesophageal reflux disease (GERD),9 and in recent decades, the use of ASMs has substantially increased in both pregnant and pediatric populations.10,11

27 July 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
HJHan Eol Jeong
Han Eol Jeong
HLHyesung Lee
Hyesung Lee
HSHyun Joon Shin
Hyun Joon Shin
YCYoung June Choe
Young June Choe
KFKristian B Filion
Kristian B Filion
JSJu-Young Shin
Ju-Young Shin
Background: Nonsteroidal antiinflammatory drugs (NSAIDs) may exacerbate coronavirus disease 2019 (COVID-19) and worsen associated outcomes by upregulating the enzyme that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in order to enter cells. Methods: We conducted a cohort study using South Korea’s nationwide healthcare database, which contains data for all individuals who received a COVID-19 test (n = 69 793) as of 8 April 2020. We identified adults hospitalized with COVID-19, where cohort entry was the date of hospitalization. NSAID users were those prescribed NSAIDs in the 7 days before and including cohort entry, and nonusers were those not prescribed NSAIDs during this period. Our primary outcome was a composite of in-hospital death, intensive care unit admission, mechanical ventilation use, and sepsis; our secondary outcomes were cardiovascular complications and acute renal failure. We conducted logistic regression analysis to estimate odds ratio (OR) with 95% confidence intervals (CIs) using inverse probability of treatment weighting to minimize confounding. Results: Of 1824 adults hospitalized with COVID-19 (mean age, 49.0 years; female, 59%), 354 were NSAID users and 1470 were nonusers. Compared with nonuse, NSAID use was associated with increased risks of the primary composite outcome (OR, 1.54; 95% CI, 1.13–2.11) but insignificantly associated with cardiovascular complications (OR, 1.54; 95% CI, 0.96–2.48) or acute renal failure (OR, 1.45; 95% CI, 0.49–4.14). Conclusions: While awaiting the results of confirmatory studies, we suggest NSAIDs be used with caution for COVID-19 patients as the harms associated with their use may outweigh their benefits.

27 February 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ECEun-Young Choi
Eun-Young Choi
HJHan Eol Jeong
Han Eol Jeong
YNYunha Noh
Yunha Noh
ACAhhyung Choi
Ahhyung Choi
DYDong Keon Yon
Dong Keon Yon
JSJu-Young Shin
Ju-Young Shin
Background: Existing data on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during late pregnancy is well established, providing assurance. However, the use of NSAIDs during early pregnancy remains inconclusive owing to conflicting findings on adverse neonatal outcomes as well as the limited data on adverse maternal outcomes. Therefore, we sought to investigate whether early prenatal exposure to NSAIDs was associated with neonatal and maternal adverse outcomes. Methods and findings: We conducted a nationwide, population-based cohort study using Korea’s National Health Insurance Service (NHIS) database with a mother–offspring cohort constructed and validated by the NHIS to include all live births in women aged 18 to 44 years between 2010 and 2018. We defined exposure to NSAIDs as at least two records of NSAID prescriptions during early pregnancy (first 90 days of pregnancy for congenital malformations and first 19 weeks for nonmalformation outcomes) and compared against three distinct referent groups of (1) unexposed, no NSAID prescription during the 3 months before pregnancy start to end of early pregnancy; (2) acetaminophen-exposed, at least two acetaminophen prescriptions during early pregnancy (i.e., active comparator); and (3) past users, at least two NSAID prescriptions before the start of pregnancy but no relevant prescriptions during pregnancy. Outcomes of interest were adverse birth outcomes of major congenital malformations and low birth weight and adverse maternal outcomes of antepartum hemorrhage and oligohydramnios. We estimated relative risks (RRs) with 95% CIs using generalized linear models within a propensity score (PS) fine stratification weighted cohort that accounted for various potential confounders of maternal sociodemographic characteristics, comorbidities, co-medication use, and general markers of burden of illness. Of 1.8 million pregnancies in the PS weighted analyses, exposure to NSAIDs during early pregnancy was associated with slightly increased risks for neonatal outcomes of major congenital malformations (PS-adjusted RR, 1.14 [CI, 1.10 to 1.18]) and low birth weight (1.29 [1.25 to 1.33]), and for maternal outcome of oligohydramnios (1.09 [1.01 to 1.19]) but not antepartum hemorrhage (1.05 [0.99 to 1.12]). The risks of overall congenital malformations, low birth weight, and oligohydramnios remained significantly elevated despite comparing NSAIDs against acetaminophen or past users. Risks of adverse neonatal and maternal outcomes were higher with cyclooxygenase-2 selective inhibitors or use of NSAIDs for more than 10 days, whereas generally similar effects were observed across the three most frequently used individual NSAIDs. Point estimates were largely consistent across all sensitivity analyses, including the sibling-matched analysis. Main limitations of this study are residual confounding by indication and from unmeasured factors. Conclusions: This large-scale, nationwide cohort study found that exposure to NSAIDs during early pregnancy was associated with slightly higher risks of neonatal and maternal adverse outcomes. Clinicians should therefore carefully weigh the benefits of prescribing NSAIDs in early pregnancy against its modest, but possible, risk of neonatal and maternal outcomes, where if possible, consider prescribing nonselective NSAIDs for <10 days, along with continued careful monitoring for any safety signals.

3 January 2023 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ACAhhyung Choi
Ahhyung Choi
YNYunha Noh
Yunha Noh
HJHan Eol Jeong
Han Eol Jeong
ECEun-Young Choi
Eun-Young Choi
KMKenneth K. C. Man
Kenneth K. C. Man
JSJu-Young Shin
Ju-Young Shin
Gastroesophageal reflux disease (GERD) is common during pregnancy, occurring in up to 80% of the pregnant population.1 Although mild symptoms can be alleviated by lifestyle modifications, acid-suppressive medications are often required for a substantial number of patients to manage their inadequately controlled symptoms. Specifically, the use of proton pump inhibitors (PPIs) during pregnancy has increased worldwide, which may be in part due to their acid-suppressing effects.2,3

20 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJeong-Seon Lee
Jeong-Seon Lee
Jae Il ShinJae Il Shin
Jae Il Shin
SKSunyeup Kim
Sunyeup Kim
YCYong-Sung Choi
Yong-Sung Choi
YSYoun Ho Shin
Youn Ho Shin
DYDong Keon Yon
Dong Keon Yon
Benefits of breastfeeding for both the mother and the child are well established, but a comprehensive and robust study to investigate the protective effect of breastfeeding and attenuated time effect stratified by cause of morbidity are lacking. This study is based on the nationwide birth cohort in Korea that includes data on all infants born from 2009 to 2015. Of 1,608,540 children, the median follow-up period was 8.41 years (interquartile range, 6.76-10.06). When compared to children with fully formula feeding, the hospital admission rate was 12% lower in those with partially breastfeeding and 15% lower in those with exclusive breastfeeding. The apparent protective effect of breastfeeding was reduced with increasing age. Our study provides potential evidence of the beneficial association of breastfeeding on subsequent hospital admissions. The protective effect declined over time as the children grew older. Encouraging any breastfeeding for at least the first 6 months among infants is an important public health strategy to improve overall child health.

2 May 2023 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
JKJu Hwan Kim
Ju Hwan Kim
HLHyesung Lee
Hyesung Lee
IOIn-Sun Oh
In-Sun Oh
HJHan Eol Jeong
Han Eol Jeong
SBSungho Bea
Sungho Bea
JSJu-Young Shin
Ju-Young Shin
Bedaquiline and delamanid were recently approved for multidrug resistant tuberculosis (MDR-TB). Bedaquiline carries a black box warning of increased risk of death compared to the placebo arm, and there is a need to establish the risks of QT prolongation and hepatotoxicity for bedaquiline and delamanid. We retrospectively analyzed data of MDR-TB patients retrieved from the South Korea national health insurance system database (2014-2020) to assess the risks of all-cause death, long QT-related cardiac event, and acute liver injury associated with bedaquiline or delamanid, compared with conventional regimen. Cox proportional hazards models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Stabilized inverse probability of treatment weighting based on propensity score was used to balance characteristics between the treatment groups. Of 1998 patients, 315 (15.8%) and 292 (14.6%) received bedaquiline and delamanid, respectively. Compared with conventional regimen, bedaquiline and delamanid did not increase risk of all-cause death at 24-month (HR 0.73 [95% CI, 0.42-1.27] and 0.89 [0.50-1.60], respectively). Bedaquiline-containing regimen increased risk of acute liver injury (1.76 [1.31-2.36]), while delamanid-containing regimen increased risk of long QT-related cardiac events (2.38 [1.05-3.57]) within 6 months of treatment. This study adds to the emerging evidence refuting the higher mortality rate observed in the bedaquiline trial population. Association between bedaquiline and acute liver injury needs careful interpretation considering for other background hepatotoxic anti-TB drugs. Our finding on delamanid and long QT-related cardiac events suggest careful risk-benefit assessment in patients with pre-existing cardiovascular disease.